The acquisition of another Israeli medtech startup by a leading global medical technology company marks a significant milestone in the development of advanced solutions for treatment-resistant hypertension. This achievement reflects a decade-long process of research, development, and technological maturation, one that GTI has been part of from the very beginning.
Over the course of roughly ten years, GTI supported the company from its founding through to product completion. The collaboration was grounded in precision engineering and manufacturing, compliance with stringent standards, and continuous support across every stage of development and the transition to serial production.
GTI provided a comprehensive service offering that included laser cutting, laser welding, surface treatments, and rigorous quality control. Beyond manufacturing, GTI played an active role in developing engineering solutions for key system components, adapting to evolving regulatory requirements and functional needs throughout the project lifecycle. Close collaboration between the engineering teams helped shorten development timelines, improve product reliability, and ensure process consistency.
We are proud to have been partners on this journey and to contribute to bringing another innovative medical technology with global potential to market. GTI is fully prepared for the next phase: serial production ahead of the planned 2027 product launch, with an unwavering commitment to quality, precision, and industrial innovation. We see this project as a testament to our ability to serve as long-term strategic manufacturing partners to medical device startups from concept through commercialization.